# Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

> **NCT00025727** · PHASE3 · UNKNOWN · sponsor: **GlaxoSmithKline** · enrollment: 330 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Lopinavir/Ritonavir
- **DRUG:** Ritonavir
- **DRUG:** GW433908

## Key facts

- **NCT ID:** NCT00025727
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 330 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025727, "Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00025727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*